## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Chang

**Application No. 09/701,536** 

Filed: June 18, 2001 Confirmation No. 5492

For: NUCLEIC ACID VACCINES FOR

PREVENTION OF FLAVIVIRUS

**INFECTION** 

Examiner: Jeffrey S. Parkin

Art Unit: 1648

Attorney Reference No. 6395-64907-01

MAIL STOP AMENDMENT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

## **CERTIFICATE OF MAILING**

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney for Applicant(s) (anya M. Harding, Ph.D.

Date Mailed October 6, 2004

## SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(c)

Listed on the accompanying form PTO-1449 and enclosed herewith are three English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent. This Supplemental Information Disclosure Statement ("IDS") is being mailed before Applicant received a final action, a notice of allowance, or an action that otherwise closes prosecution in the referenced application.

Submitted herewith is a check for \$180.00 as required by 37 C.F.R. § 1.17(p) for filing this IDS in compliance with 1.97(c). Please charge any additional fees which may be required in connection with filing this Supplemental IDS, or credit any overpayment. Deposit Account Authority is given on the attached transmittal sheet.

10/13/2004 KBETEMA1 00000003 09701536

01 FC:1806

180.00 OP

TMH:dv 10/06/04 6395-64907-01 PATENT

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LJLP

By

Tanya M. Harding, Ph.D. Registration No. 42,630

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

cc: Docketing

TMH:dv	10/06/04 6395-64907-01	
	(m)	
	( 2 007 1 2 2004 E)	

Attorney Docket Number	6395-64907-01
Application Number	09/701,536
Filing Date	June 18, 2001
First Named Inventor	Chang
Art Unit	1648
Examiner Name	Jeffrey S. Parkin

		Examiner Name Jenrey S. Parkin		
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS		
		Cavener and Ray, "Eukaryotic start and stop translation sites," <i>Nucleic Acids Research</i> , 19(12):3185-3192 (1991)		
		Kozak, "At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells," <i>J. Mol. Biol.</i> , 196:947-950 (1987)		
		Kozak, "Point Mutations Define a Sequence Flanking the AUG Initiator Codon That Modulates Translation by Eukaryotic Ribosomes," <i>Cell</i> , 44:283-292 (January 31, 1986)		
		· · · · · · · · · · · · · · · · · · ·		

EXAMINER DAT SIGNATURE: CON	E SIDERED:
-----------------------------	---------------

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.